|Bid||12.48 x 800|
|Ask||13.53 x 900|
|Day's Range||12.00 - 12.65|
|52 Week Range||10.89 - 27.00|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.86|
Subscribe to Yahoo Finance Plus to view Fair Value for RNA
The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Avidity Biosciences ( NASDAQ:RNA ) Third Quarter 2022 Results Key Financial Results Net loss: US$43.6m (loss widened by...
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?